Innorna Awarded "2025 Forbes China Leading Enterprises in Industry Development"

Boston, Hong Kong, Shenzhen - March 14, 2025 – Innorna, a pioneering mRNA/LNP biotechnology company, is thrilled to announce its selection as one of the “2025 Forbes China Leading Enterprises in Industry Development.” This prestigious award honors Innorna’s groundbreaking innovation and remarkable contributions to advancing mRNA-LNP technology. Notably, Innorna is the only mRNA-LNP technology company to receive this distinction, underscoring its leadership and transformative impact within the industry.

Organized by Forbes China in collaboration with global consultancy Frost & Sullivan, this annual selection spotlights enterprises and visionaries driving transformative innovation across diverse sectors. Renowned for its impartial evaluation criteria, the list sets a benchmark for excellence in technological advancement and market leadership. Innorna’s inclusion shines a spotlight on its unparalleled expertise in mRNA-LNP technology - a groundbreaking enabler of next-generation nucleic acid therapeutics. This recognition not only celebrates Innorna’s remarkable achievements but also signals its immense potential to shape the future of medicine.

Dr. Linxian Li, Founder and CEO of Innorna, expressed heartfelt gratitude: “We are deeply honored to receive the ‘2025 Forbes China Leading Enterprises in Industry Development’ award. This distinction is a testament to the relentless dedication of our team and the unwavering support of our partners. mRNA-LNP technology holds immense potential to revolutionize drug development, and we remain steadfast in our commitment to accelerating its application to address unmet medical needs through innovation and collaboration.”

About the "2025 Forbes China Pioneer Innovators in Industry Development"

Launched in late November 2024 by Forbes China in collaboration with Frost & Sullivan, this prestigious initiative highlights excellence across key sectors, including AI technology, broad consumption, biopharmaceuticals, renewable energy, finance, and internet services. Drawing on their unparalleled industry expertise and media resources, the selection process employed meticulous data analysis and comprehensive market research to identify and celebrate enterprises and individuals making transformative contributions in China and beyond.

The journey culminated on March 21, 2025, as the esteemed judging panel convened in Shanghai for the final review, following months of rigorous evaluation. The official list of honorees was unveiled shortly thereafter, recognizing the trailblazers driving innovation and influence across industries. The celebrations reached their peak on March 22, 2025, at the Gala Evening of Honor in Shanghai, where distinguished enterprises and visionaries gathered to commemorate this extraordinary achievement.

About Innorna

Founded in 2019, Innorna is committed to developing state-of-the-art LNP delivery technology and RNA-based therapies to address unmet medical needs. The company’s proprietary Diversity-Oriented Lipid Library (DOLL), housing over 5,000 ionizable lipids, has laid the foundation for breakthroughs across mRNA vaccines, gene editing, and cell therapy.

With its innovative mRNA-LNP platform, Innorna has built a robust pipeline targeting infectious diseases, rare genetic disorders, and cancer immunotherapy. Beyond its internal R&D efforts, the company collaborates with global leading biotechnology partners to expand the reach of its transformative technology.

Innorna’s achievements have garnered widespread recognition, including accolades from MIT Technology Review as one of the Global Top 50 Smartest Companies and Fortune China as one of the Most Socially Influential Startups. The company’s core values - INNOVATION, EFFICIENCY, INTEGRITY, and OPENNESS - drive its mission to revolutionize mRNA applications and make a global impact.

For more information, please visit www.innorna.com